An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian stent to be non-inferior and resulted in significantly lower Target Lesion Failures, including cardiac death and heart attacks.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aiTWQR7
via IFTTT
No comments:
Post a Comment